Neuland Labs and LIR Life Sciences Partner to Develop Transdermal GLP-1 Obesity Treatment Using Cell-Penetrating Peptide Platform

Neuland Laboratories and LIR Life Sciences are collaborating to develop a transdermal Glucagon-like peptide-1 (GLP-1) for obesity treatment. The partnership will focus on developing a cell-penetrating peptide (CPP) platform.

The collaboration leverages Neuland Laboratories’ expertise in peptide synthesis and LIR Life Sciences’ capabilities in transdermal drug delivery. The goal is to create a new method of obesity treatment using a transdermal patch that delivers GLP-1 peptides through the skin. The CPP platform will facilitate the delivery of the peptide.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: May 7, 2026

Author

GOAI